NO EFFECT OF CLORICROMEN ON SOME COAGULATION PARAMETERS IN PATIENTS WITH ISCHEMIC CEREBROVASCULAR-DISEASE

Cloricromen is a new drug that inhibits platelet aggregation in man an d in experimental thrombosis. Twenty patients with a history of athero thrombotic stroke received cloricromen (100 mg, twice daily) for 30 da ys in order to evaluate its effects on plasma fibrinogen, antithrombin III, and other variables of the haemostatic system. A statistically s ignificant decrease in the prothrombin time (P < 0.01) was found only after 30 days of therapy. This decrease was transient and disappeared 15 days after the end of treatment. No statistically significant chang es in plasma fibrinogen levels, antithrombin III, partial thromboplast in time, or platelet count were observed compared with baseline values . No side-effects were reported. This study did not reveal an effect o f cloricromen on coagulative variables in patients with cerebrovascula r occlusive disease.